Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
.0005s starting 👀
Over 100 million in the first 5 min 👀🚀
NEWS - https://www.otcmarkets.com/stock/FLES/news/story?e&id=2771412
Auto Parts 4 Less Group Inc. Announces Major Debt Restructuring and Continuation of Growth Strategy
RENO, Nev., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Auto Parts 4 Less Group Inc. (OTC: FLES) (the “Company,” “AutoParts4Less,” “FLES”), the operator of the specialized automotive parts marketplace AutoParts4Less.com, today shared a notable investor update from the Company's CEO, who announced a significant restructuring of its debt obligations. The company has entered into agreements with Auctus Investment Group and Growth Ventures to convert a combined total of $7,439,599 of outstanding debt into a preferred share structure. This strategic move is expected to enhance the company's balance sheet and provide greater financial flexibility.
Christopher Davenport, CEO of Auto Parts 4 Less Group Inc., stated: "We are thrilled to announce this significant milestone in our ongoing efforts to strengthen our financial position. By converting over $7 million of debt into preferred shares, we are not only reducing our liabilities but also minimizing dilution for our existing shareholders. This restructuring, along with our continued collaboration with current lenders to convert debt, underscores our commitment to creating value for our stakeholders and ensuring the long-term success of our company."
The preferred shares are convertible into shares of Company common stock, including on a mandatory basis upon the occurrence of an uplisting to the NASDAQ or NYSE stock exchanges. The preferred shares may not be converted for a period of one year, but are, thereafter, convertible into shares of Company common stock. Further information concerning this restructuring is available in the Company’s filed Current Report on Form 8-K.
Auto Parts 4 Less Group Inc. remains committed to its mission of operating an automotive parts only marketplace, connecting buyers directly (D2C) and business-to-business (B2B) with the largest and most trusted sellers of automotive parts in the world. By leveraging the $500 billion U.S. automotive parts sector, the company aims to provide a seamless and reliable platform for high-quality automotive parts and accessories at competitive prices.
For more information about Auto Parts 4 Less Group Inc., please visit www.AutoParts4LessGroup.com
About Auto Parts 4 Less Group Inc.
Auto Parts 4 Less Group Inc. (OTC: FLES) entered the online auto parts business in 2015, selling lift kits and other aftermarket accessories for Jeeps, Trucks, and SUVs on eBay and Amazon. In early 2020, the Company began developing AutoParts4Less.com as a multi-seller enterprise-level marketplace dedicated to consolidating the $500 billion annual aftermarket automotive parts industry, including cars, trucks, boats, motorcycles, and RVs, on a single platform. AutoParts4Less.com officially launched with a catalogue size of around 2 million parts from over 25 parts sellers in November 2022.
Replay recorded 2-18-2024 FLES CEO update call:
https://t.co/p8uC4d7Y6E$FLES See everyone tonight at 7PM EST! Come on down to the LIVE Q&A! I'll also provide a brief update on my positions & thoughts moving forward on: $ILUS $IGPK $CYBL $IFUS $BIXT & maybe a few more contingent on time! @AP4Less #podcasting #stocks
— Buffalo Fireside Chats (@buffalofireside) February 18, 2024
Sunday February 18th 2024 7pm EST - BFC LIVE | FLES STOCK | CEO Chris Davenport | EROCK PORTFOLIO UPDATE!
https://twitter.com/AP4Less/with_replies
https://t.co/xnUckrUERX
— Buffalo Fireside Chats (@buffalofireside) February 16, 2024
Good Morning, BFC Community! It's been quite a week for us! Have a great Friday and an enjoyable extended weekend! Big show on Sunday with CEO Chris Davenport @AP4Less of $FLES at 7PM EST. Come do some LIVE DD!
Cheers Bulls! ...and even you bears!
https://t.co/tR6u7i3x5Q$FLES was just added to the BFC watchlist. Join me as I sit down with CEO Chris Davenport of @AutoParts4_less. @BrettRosen325 mentioned this in one of our recent shows! Thanks for reaching out to set this up.
— Buffalo Fireside Chats (@buffalofireside) February 3, 2024
BRING ON THE QUESTIONS BFC COMMUNITY!
FLES nice volume over 1.2 million and up over 100% today 👀
CGAC went up 8% today - Overall Average: 88% BUY
https://www.barchart.com/stocks/quotes/CGAC/opinion
We could be @ 100% next week 👀
Would be nice to get back on IHub "Most Read Boards and BOB"
to get more 👀 here looking 🤑 @ CGAC potential move up
gms I will "get more shares" under .0005 is bargain pricing 🛒
I am still adding on the dips also for the big move
Onward and Upward 😎
I see 👀 big things happening with CGAC
Holding my many millions for the take off 🚀
CGAC Overall Average: 80% BUY 👀
https://www.barchart.com/stocks/quotes/CGAC/opinion
Good Friday moning train and DPLS 👀
FLES up 65% and nice volume today 👀
Good Friday morning BDEZ, Trader53 and DPLS 😎
Good morning TXTM 👀
Clean Vision Corporation Announces Launch of $340 Million Green Bond
Tuesday, 23 January 2024 09:00
https://www.accesswire.com/827240/clean-vision-corporation-announces-launch-of-340-million-green-bond
morning Back, sorry to hear about your Dad,
I lost my Dad back in 1996 and my Mom 1995
its always hard to see loved ones go
Good morning Steve and CLNV 🚀
CLNV at the 34:43 min mark WOW 🚀
Good morning TPTW 👀
GM CLNV still holding strong 👀
Therapeutic Solutions International Subsidiary Immunotherapy Company Res Nova Bio, Inc. Announces Positive Data on First Four Advanced Cancer Patients Treated with FloraStilbene™BUSINESS WIRE | 01/03/2024
https://www.otcmarkets.com/stock/TSOI/news/story?e&id=2730465
https://www.otcmarkets.com/stock/TSOI/news
Hoping for a better 2024 ahead
Have a Happy New Year everyone 😎
Merry Christmas to all and to all a good night 🚀
8K out - Letter to Shareholders and Interested Parties. - Item 8.01 Other Events –
https://www.otcmarkets.com/filing/html?id=17139397&guid=zrJ-ka87g1i-B3h
Dear Shareholders and all Interested Parties,
As we come to the end of another year at Therapeutic Solutions International (TSOI), we would like to take a moment to spotlight the numerous accomplishments we have achieved throughout this year.
In January, we introduced groundbreaking data and initiated a patent filing based on a surprising discovery. This discovery involves the application of multiple microinjections containing peptides derived from myelin basic protein, combined with various agents designed to inhibit the maturation of dendritic cells. The result? A significantly enhanced suppression of symptoms related to multiple sclerosis within the experimental autoimmune encephalitis model, when compared to traditional administration methods1.
In February, we inaugurated the Veltmeyer Institute for Advanced Biologics. Our primary mission is to offer patients access to JadiCell adult stem cell treatments, specifically in the realm of brain and lung conditions, under the provisions of the Right to Try Law (`RTT) when it is applicable. Additionally, we extend our services to cancer patients, providing a range of immunotherapies, including ValloVax and FloraVax2.
In April, we submitted a fresh Phase III clinical trial application to the FDA. This application seeks approval for the utilization of our JadiCell in the treatment of acute respiratory distress syndrome (ARDS)3.
In May, we introduced VasoSome Vascular, Inc., with a strong focus on addressing the critical issue of aortic aneurysms, often referred to as the “living timebomb” condition. We are pioneering the use of stem cell-derived exosomes in our approach4.
Simultaneously in May, we made an exciting announcement about the establishment of CTE Biologics, Inc., as a subsidiary company. This new entity is wholly dedicated to the commercialization of the JadiCell adult stem cell platform, specifically for the treatment of chronic traumatic encephalopathy5.
In June, we applied to the FDA requesting “Orphan Drug Designation” for our JadiCell Adult Stem Cell Product, specifically for the treatment of acute respiratory distress syndrome (ARDS). If granted, this designation would make JadiCells eligible for several significant benefits and incentives. These include seven years of exclusive marketing rights, tax credits for clinical trials, eligibility for orphan drug grants, and exemption from FDA New Drug Application fees6.
In July, we continued our momentum by submitting another application to the FDA, this time seeking Orphan Drug Designation for JadiCell in the treatment of Frontotemporal Dementia. Research has highlighted various inflammatory mechanisms as contributors to disease progression in both chronic traumatic encephalopathy and frontotemporal dementia. One particularly intriguing aspect of our research revolves around the capacity of JadiCells to not only inhibit inflammasome activation but also to target downstream chemical messengers within this inflammatory pathway. Simultaneously, JadiCells demonstrate the ability to stimulate the regeneration of damaged neurons, making them a promising candidate for addressing these challenging neurological conditions7.
In August, we proudly announced a significant achievement within our subsidiary, Allogen Biologics, Inc. They successfully created a Master Cell Bank (MCB) containing our JadiCell, which has undergone rigorous quality control testing. It is estimated that by August 2024, these cells will have matured to a level that allows us to obtain clearance for Phase III Investigational New Drug (IND) trials. Importantly, this MCB serves a dual purpose by not only supplying cells for clinical trials but also making them available for Right to Try (RTT) cases in the interim period8.
In the most recent month of December, we unveiled our latest endeavor by establishing our eighth subsidiary company, ALS Biologics, Inc. This company is solely committed to addressing Amyotrophic Lateral Sclerosis (ALS), a debilitating motor neuron degenerative disease that currently lacks a cure. The formation of ALS Biologics, Inc. was prompted by encouraging observations from patients who underwent treatment with our ALScell™ (JadiCell™) product under the Right to Try Law at the Veltmeyer Institute9.
1 Therapeutic Solutions International Announces Antigen Specific Blockade of Pathological Immune Response in Multiple Sclerosis Model Using “Tattoo Gun” Immunization
2 Therapeutic Solutions International Launches Veltmeyer Institute for Advanced Biologics
3 Therapeutic Solutions International Files to Initiate Phase III Clinical Trial for Acute Respiratory Distress Syndrome (ARDS) Leveraging Positive COVID-19 Data with JadiCell Stem Cell Therapy
4 Therapeutic Solutions International Launches VasoSome Vascular Inc Based on Successful Treatment of Aortic Aneurysms using Patent Pending Exosome Therapy
5 Therapeutic Solutions International Launches Subsidiary Company to Commercialize Clinical Data and IND for Treatment of Chronic Traumatic Encephalopathy (CTE) with JadiCell Universal Adult Stem Cells
6 Therapeutic Solutions International Files for Orphan Drug Designation Using JadiCell Adult Universal Donor Stem Cells for Treatment of Acute Respiratory Distress Syndrome
7 Therapeutic Solutions International Files for Orphan Drug Designation Use of JadiCell Adult Stem Cells for Treatment of Frontotemporal Dementia
8 Therapeutic Solutions International Subsidiary Allogen Biologics Inc. Successfully Manufactures JadiCell Master Cell Bank to Provide Cells for Right to Try Use and Phase III ARDS Clinical Trial
9 Therapeutic Solutions International Announces Formation of ALS Biologics Inc to Commercialize Regenerative Technologies Related to Dreaded Motor Neuron Disease
Furthermore, the company has filed a total of six (6) new patent applications, and two (2) additional patents have been granted this year. As a result, our patent portfolio has expanded to encompass 77 patents and patent applications. Additionally, our drug pipeline has seen substantial growth, now comprising 34 drugs at various stages of testing and development.
The incredible advancements in science and research owe their success to our immensely dedicated team of researchers, clinicians, partner institutions, and other collaborators who steadfastly collaborate with TSOI year after year. Personally, I am eternally grateful to each and every one of them.
This year has also brought forth significant revelations, which we have meticulously documented through the submission of two 8K reports and, most recently, two amicus briefs (See Exhibits 99, 99.1) filed in the United States Court of Appeals for the Federal Circuit. These filings are associated with the case of RESTEM, LLC, (Appellant) v. JADI CELL, LLC, (Appellee), specifically identified as Case # 2023-2054. This matter is currently under appeal from the United States Patent and Trademark Office, Patent Trial and Appeal Board, docketed as No. IPR2021-01535. All of these developments are centered around our Exclusive World-Wide Patent Licensing for Lung and Brain applications utilizing the JadiCell.
As we set our sights on 2024, TSOI is committed to advancing its research and development initiatives. We aim to forge new frontiers in medicine, with the aspiration of uncovering groundbreaking discoveries that will pave the way for innovative medications, fresh patent applications, and investigational drug submissions. Furthermore, we have ambitious plans to introduce additional subsidiary companies throughout 2024, with a specific focus on diseases such as epilepsy, multiple sclerosis, cognitive dysfunction, and various lung and brain pathologies. These endeavors will leverage the power of regenerative medicine, immunotherapies, and other complementary approaches to address these critical health challenges.
Our maiden subsidiary, Campbell Neurosciences, Inc., has been diligently preparing for its transition to the public domain, following the earlier announcement of a shareholder dividend this year. We are pleased to report that we have successfully concluded the sixth round of inquiries and document submissions to FINRA. As a result, we anticipate the final stages of this process with FINRA, marking a significant milestone on our path to taking Campbell Neurosciences public in 2024. This endeavor represents an innovative approach to bringing a company to the public sphere, in alignment with the new corporate action proposal we have submitted to FINRA.
As we conclude this year, we eagerly anticipate the opportunities that the new year will unfold. We extend our heartfelt gratitude to every individual within TSOI who has dedicated their unwavering efforts throughout the past year. We also express our appreciation to our subsidiary companies and their investors, as well as the steadfast support of our advocates and shareholders within TSOI. Together, we look ahead to a promising future filled with innovation and progress...
Morning Steve and CLNV
Has anyone tried buying an EM/Expert Market stock like with TXTM - CE
with https://speedtrader.com ??
Thanks
TXTM @ .0025 up over 50% 🚀
Good morning DPLS, subs and T53 looking 👀 for some Green today 🚀
More TXTM green today, up 23% to .0016 🚀
Good hump day morning to CLNV longs 🚀
TXTM @ .0013 up over 85% today, nice and Green p2020 😎
IQST - iQSTEL Exceeds $120 Million 2023 Annual Revenue Forecast Before EOY
https://www.otcmarkets.com/stock/IQST/news/IQST---iQSTEL-Exceeds-120-Million-2023-Annual-Revenue-Forecast-Before-EOY?id=424473
PR Newswire
NEW YORK, Dec. 12, 2023 /PRNewswire/ -- iQSTEL Inc. (OTC-QX: IQST) today announced the company has already exceeded its FY-2023 $120 million annual revenue forecast based on preliminary accounting.
Thanks subs, TSOI onward and upward